StockNews.AI
ELAB
StockNews.AI
174 days

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

1. PMGC announced its capital structure and financial position as of February 25, 2025. 2. Common shares outstanding total 4,042,295 with no debt reported. 3. Recent capital raises include $8.0 million in September 2024. 4. NorthStrive Biosciences develops EL-22, targeting obesity and muscle preservation. 5. Strong capital position positions PMGC for ongoing strategic growth.

7m saved
Insight
Article

FAQ

Why Bullish?

The company's strong capital position and absence of debt could attract investors. Historical examples show that companies with low debt often experience stock price appreciation.

How important is it?

The article contains crucial information about funding and strategic growth priorities that can significantly impact ELAB’s market performance.

Why Long Term?

The strategic focus on growth through subsidiaries like NorthStrive and PMGC Capital is designed for sustainable long-term value. Companies investing in R&D often see delayed but significant returns.

Related Companies

NSTRPMGC
NEWPORT BEACH, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company,” “PMGC,” “us,” or “we”) (Nasdaq:ELAB), a diversified holding company, today announced an update on its capital structure, highlighting its financial position and ongoing commitment to executing its strategic priorities through its operating subsidiaries. As of February 25, 2025, PMGC’s capital structure is as follows: Common Shares Outstanding: 4,042,295.Stock Options Outstanding: 4,931 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $304 per share.Warrants Outstanding: 979,814 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted-average exercise price of $4.91 per share, including: 969,386 shares issuable upon the exercise of warrants with an exercise price of $2.75 per share.All warrants are standard, “plain vanilla” warrants with no ratchet provisions. Debt: The Company has zero debt.Short Interest: As of January 31, 2025, the short interest in the Company was 334,969 shares, according to The Nasdaq Stock Market LLC. Recent Capital Raises September 2024 – The Company raised $8.0 million in gross proceeds via an S-1 offering of common stock, pre-funded warrants and Series A and Series B warrants. All warrants associated with this raise have been exercised. Filing here: XBRL ViewerJanuary 2025 – The Company received approximately $1.9 million in gross proceeds via a warrant inducement offering with certain institutional investors. Filing here: Inline Viewer: PMGC Holdings Inc. 8-K 2025-01-27 PMGC believes it currently has a strong capital position and is poised to continue executing its strategic priorities through its operating subsidiaries, set forth below: NorthStrive Biosciences Inc. – A biopharmaceutical company focused on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, leverages an engineered probiotic approach to address a pressing issue in the obesity market, preserving muscle in patients undergoing weight loss treatments, including GLP-1 receptor agonists. For more information, visit northstrivebio.com.PMGC Research Inc. – A research and development subsidiary which utilizes Canadian research grants and partners with leading Canadian universities to accelerate scientific discovery and transform cutting-edge technologies into commercially viable products.PMGC Capital LLC – A multi-strategy investment firm focused on direct investments, strategic lending, and the acquisition of undervalued companies and assets across diverse markets. The firm’s mission is to identify and seize high-potential opportunities in order to deliver sustainable growth and maximize returns on capital. The Company believes it currently has a strong balance sheet and a well-defined business focus. PMGC Holdings remains dedicated to innovative solutions and delivering long-term value for its shareholders. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact:IR@pmgcholdings.com

Related News